Oncology

Findings from a systematic review found little difference in outcomes between biosimilar and reference product treatment options.

Cancer misinformation may be more prevalent among residents in rural vs urban areas, study finds.

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19.

Jenny Sherak, president of Specialty Physician Services at AmerisourceBergen sat down with Drug Topics® to discuss how her team provides the best customer experiences for community oncology practices across the United States.

President Biden is reviving the program he headed as vice president, with the goal of reducing the cancer mortality rate and improving the experience of patients and their loved ones.

Human papillomavirus (HPV) vaccination has significantly decreased the incidence and mortality of cervical cancer in girls and women between the ages of 15 and 24, according to a research letter in JAMA Pediatrics.

A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

Breast cancer continues to affect women globally, with approximately 13% developing invasive disease. New treatment regimens and options are on the horizon for breast cancer therapy.

The FDA has accepted for review a biologics license application for the use of toripalimab in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma.

A new drug candidate demonstrated the potential to control inflammation for cancer patients in findings that were recently announced in Proceedings of the National Academy of Sciences.

In a study conducted, antidepressants slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they stopped cancer growth long-term.

IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.

An expert highlights the progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

The consumer products giant voluntarily recalled 4 NEUTROGENA® and 1 AVEENO® spray sunscreen products July 14 after internal testing found low levels of benzene, a carcinogen, in some product samples.

A study from the 2021 ASCO Annual Meeting examined the effect that oral anticancer agent initiation may have on adherence rates in patients with multiple myeloma and chronic conditions.

A study from the 2021 ASCO Annual Meeting assessed the prevalence of oncology drug shortages and how they hinder care for patients with cancer.

A poster presentation at the 2021 ASCO Annual Meeting discussed survival trends among patients with chronic lymphocytic leukemia.

A community oncology practice implemented a team-based approach to utilizing biosimilars.

Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.

A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.

Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.

Findings from the phase 3 RELATIVITY-047 trial were presented at the 2021 ASCO Annual Meeting.

The FDA has approved sotorasib (Lumakras; Amgen Inc) for the treatment of non-small cell lung cancer in patients with KRAS G12C genetic mutations and who have received at least 1 prior therapy.